Inhibrx Biosciences Q3 net loss $43.9M ($2.84/shr); cash $196.3M; trial readouts in next 12 months

Inhibrx Biosciences, Inc.

2024-Q3 EPS reported $117.09 revenue$100,000

Cash and cash equivalents $196.3M as of Sep 30, 2024, down from $226.9M at June 30, 2024.
Net loss of $43.9M ($2.84 per share) vs $51.8M ($4.39 per share) in Q3 2023.
R&D expense $38.9M, up slightly from $38.1M, driven by expansion of Phase 2 trial for ozekibart (INBRX-109) and INBRX-106 trials.
No outstanding third-party debt post-spin-off; other income of $2.9M from interest on cash balances.
Company expects data readouts for its two ongoing clinical programs within the next 12 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.